

DELPHION

No acti

Select CR

RESEARCH**PRODUCTS****INSIDE DELPHION**

Log Out Work Files Saved Searches

My Account

Search: Quick/Number Boolean Advanced

Derwent RecordView: [Expand Details](#) Go to: [Delphion Integrated View](#)

Tools: Add to Work File: Create new

Derwent Title: **Compsn. for transdermal admin. of active agents, partic. vitamin D3 - which are lipophilic, comprises lipophilic active agent, silicone-based adhesive polymer compsn., absorption promoter and volatile solvent**

Original Title: **EP0679392A1**: Pharmaceutical form for transdermal administration

Assignee: **LAURENT P** Individual
LAB LAFON SA L Standard company
 Other publications from **LAB LAFON SA L (LAFO)**...

Inventor: **LAURENT P**;

Accession/Update: **1995-374953 / 200325**

IPC Code: **A61K 0/00 ; A61K 9/00 ; A61K 9/06 ; A61K 9/70 ; A61K 31/56 ; A61K 47/30 ; A61K 47/34 ; A61K 6/00 ; A61K 7/021 ; A61K 7/44 ; A61K 9/10 ; A61K 31/59 ; A61K 47/10 ; A61K 47/14 ; A61K 47/32 ; A61L 24/04 ; A61L 25/00 ; A61L 26/00 ;**

Derwent Classes: **A96; B07; D22; P34;**

Manual Codes: **A06-A00E3**(Inorganic silicon polymers use as medical, dental, cosmetic and veterinary) , **A12-V01**(Medicines, pharmaceuticals) , **B03-G**(D (calciferol)) , **B04-C03D** (Natural, other condensation [exc. polyethers]) , **B12-M02F**(Transdermal) , **D09-C**(Bandages, dressings [general and others])

Derwent Abstract: (**EP0679392A**) Compsn. designed to form a film on the skin for transdermal admin. of an active agent, comprises: a) a lipophilic active agent, b) 5-60 wt.% of a silicone-based adhesive polymer compsn. c) 0-25 wt.% of an absorption promoter, and d) 25-95 wt.% of a volatile solvent.
Use - Use of the compsn. for the transdermal admin. of active agents, pref. vitamin D3, is claimed.

Advantage - The claimed compsn. is simple to make and does not require complex industrial machinery. It is cheap, unlike systems of prior art. It has a range of application and use. Transdermal admin. of active agents has many advantages including reduced side-effects, prolonged use with a constant plasma concn. of active agent which is not degraded by initial passage through the liver or in the digestive tract, and good patient tolerance.

Dwg.0/0

Family:

PDF Patent	Pub. Date	Derwent Update	Pages	Language	IPC Code
EP0679392A1 *	1995-11-02	199549	11	French	A61K 9/70
Des. States: (R) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
Local appls.: EP1995000400949 Filed:1995-04-26 (95EP-0400949)					
US6538039 =	2003-03-25	200325	7	English	A61K 47/30
Local appls.: US1996000741967 Filed:1996-10-31 (96US-0741967)					
CIP of US1995000428958 Filed:1995-04-26 (95US-0428958)					

<input checked="" type="checkbox"/>	<u>HU0221599B1</u> =	2002-11-28	200309	English	A61K 9/70
	Local appls.: Previous Publ. <u>HU00075251</u> (HU 75251)				
					<u>HU1995000001245</u> Filed:1995-04-28 (95HU-0001245)
<input checked="" type="checkbox"/>	<u>US20020111387A1</u> =	2002-08-15	200256	8 English	A61K 9/00
	Local appls.:				
<input checked="" type="checkbox"/>	<u>ES2169746T3</u> =	2002-07-16	200256	Spanish	A61K 9/70
	Local appls.: Based on <u>EP00679392</u> (EP 679392)				
					<u>EP1995000400949</u> Filed:1995-04-26 (95EP-0400949)
<input checked="" type="checkbox"/>	<u>DE69524470E</u> =	2002-01-24	200215	German	A61K 9/70
	Local appls.: Based on <u>EP00679392</u> (EP 679392)				
					<u>DE1995000624470</u> Filed:1995-04-26 (95DE-0624470)
					<u>EP1995000400949</u> Filed:1995-04-26 (95EP-0400949)
<input checked="" type="checkbox"/>	<u>EP0679392B1</u> =	2001-12-12	200204	10 French	A61K 9/70
	Des. States: (R) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE				
	Local appls.: <u>EP1995000400949</u> Filed:1995-04-26 (95EP-0400949)				
<input checked="" type="checkbox"/>	<u>TW0448050A</u> =	2001-08-01	200222	XX_XX	A61K 31/56
	Local appls.: <u>TW1995000106070</u> Filed:1995-06-14 (95TW-0106070)				
<input checked="" type="checkbox"/>	<u>CA2148112C</u> =	2001-01-30	200117	English	A61K 47/34
	Local appls.: <u>CA1995002148112</u> Filed:1995-04-27 (95CA-2148112)				
<input checked="" type="checkbox"/>	<u>KR0233770B1</u> =	1999-12-01	200111	English	A61K 9/70
	Local appls.: <u>KR1995000010376</u> Filed:1995-04-28 (95KR-0010376)				
<input checked="" type="checkbox"/>	<u>JP02740465B2</u> =	1998-04-15	199820	6 English	A61K 9/70
	Local appls.: Previous Publ. <u>JP08059456</u> (JP 8059456)				
					<u>JP1995000106274</u> Filed:1995-04-28 (95JP-0106274)
<input checked="" type="checkbox"/>	<u>AU0680731B</u> =	1997-08-07	199740	English	A61K 9/70
	Local appls.: Previous Publ. <u>AU09517675</u> (AU 9517675)				
					<u>AU1995000017675</u> Filed:1995-04-28 (95AU-0017675)
<input checked="" type="checkbox"/>	<u>HU0075251T</u> =	1997-05-28	199803	English	A61K 9/70
	Local appls.: <u>HU1995000001245</u> Filed:1995-04-28 (95HU-0001245)				
<input checked="" type="checkbox"/>	<u>NZ0272014A</u> =	1997-05-26	199727	English	A61K 9/06
	Local appls.: <u>NZ1995000272014</u> Filed:1995-04-28 (95NZ-0272014)				
<input checked="" type="checkbox"/>	<u>ZA9503392A</u> =	1996-12-31	199707	15 English	A61K 0/00
	Local appls.: <u>ZA1995000003392</u> Filed:1995-04-26 (95ZA-0003392)				
<input checked="" type="checkbox"/>	<u>JP08059456A</u> =	1996-03-05	199619	7 English	A61K 9/70
	Local appls.: <u>JP1995000106274</u> Filed:1995-04-28 (95JP-0106274)				
	<u>AU9517675A</u> =	1995-11-16	199602	English	A61K 9/70
	Local appls.: <u>AU1995000017675</u> Filed:1995-04-28 (95AU-0017675)				
<input checked="" type="checkbox"/>	<u>FR2719220A1</u> =	1995-11-03	199550	10 French	A61K 9/00
	Local appls.: <u>FR1994000005272</u> Filed:1994-04-29 (94FR-0005272)				
<input checked="" type="checkbox"/>	<u>CA2148112A</u> =	1995-10-30	199611	English	A61K 47/34
	Local appls.: <u>CA1995002148112</u> Filed:1995-04-27 (95CA-2148112)				

⌘ INPADOC [Show legal status actions](#)

Legal Status:

⌘ First Claim: [Show all claims](#) 1. Composition destinée à former sur la peau une pellicule pour l'administration transdermique d'un principe actif, qui comprend :

- a) un principe actif lipophile
- b) de 5 à 60 % en poids d'une composition polymère adhésive à base de silicone
- c) de 0 à 25 % en poids d'un promoteur d'absorption et
- d) de 25 à 95 % en poids d'un solvant volatil.